Amicus Therapeutics is a global biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases.

Shares

Amicus Therapeutics is currently developing migalastat, an oral drug designed to bind to and stabilize the α‐Gal A that is made in the patient’s own cells, with the intention of enabling its trafficking to lysosomes. Once delivered to lysosomes, the α‐Gal A enzyme can degrade the accumulated GL-3.

This approach is designed for patients with amenable mutations that could be capable of responding to oral migalastat as a monotherapy treatment on the basis of their genotype.

For Fabry disease patients who do not have amenable mutations, Amicus Therapeutics is investigating migalastat in combination with a novel ERT. In combination with ERT, migalastat is designed to bind to infused α‐Gal A in circulation with the intention of stabilizing the active form of the enzyme.

For more information on the development status of migalastat as a treatment option for Fabry disease, please click here.

Close

Contact Us

If have any questions or would like to get involved, please fill in the form below.

Subscribe error, please review your email address.

Close

You're now subscribed, thank you!

Close

There was a problem with your submission. Please check the field(s) with red label below.

Close

Your message has been sent. We'll get back to you soon!

Close